Human DNA-binding protein Ikaros(IKZF1) ELISA kit

Code CSB-EL011575HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name IKAROS family zinc finger 1 (Ikaros)
Alternative Names CLL associated antigen KW 6 ELISA Kit; DNA-binding protein Ikaros ELISA Kit; hIk 1 ELISA Kit; Hs.54452 ELISA Kit; IK1 ELISA Kit; Ikaros (zinc finger protein) ELISA Kit; IKAROS ELISA Kit; IKAROS family zinc finger 1 (Ikaros) ELISA Kit; Ikaros family zinc finger protein 1 ELISA Kit; Ikzf1 ELISA Kit; IKZF1_HUMAN ELISA Kit; LYF1 ELISA Kit; Lymphoid transcription factor LyF-1 ELISA Kit; PRO0758 ELISA Kit; Zinc finger protein subfamily 1A 1 (Ikaros) ELISA Kit; Zinc finger protein subfamily 1A 1 ELISA Kit; Zinc finger protein; subfamily 1A; member 1 ELISA Kit; ZNFN1A1 ELISA Kit
Abbreviation IKZF1
Uniprot No. Q13422
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 31.25 pg/mL-2000 pg/mL
Sensitivity 7.8 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Others
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human IKZF1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 88
Range % 84-95
1:2 Average % 90
Range % 85-96
1:4 Average % 87
Range % 84-93
1:8 Average % 94
Range % 90-97
The recovery of human IKZF1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 96 90-101
EDTA plasma (n=4) 89 85-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
2000 2.105 1.952 2.029 1.859
1000 1.644 1.537 1.591 1.421
500 1.022 1.011 1.017 0.847
250 0.608 0.636 0.622 0.452
125 0.397 0.383 0.390 0.220
62.5 0.309 0.304 0.307 0.137
31.25 0.241 0.248 0.245 0.075
0 0.168 0.171 0.170  
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Transcription regulator of hematopoietic cell differentiation
Gene References into Functions
  1. The cumulative recurrence rate of the children with non-functional subtypes of IKZF1 was significantly higher than that of those with functional types of IKZF1. PMID: 30022754
  2. heterozygous mutation decreases plasmacytoid dendritic cell numbers and expands conventional dendritic cells PMID: 29588478
  3. IKZF1 has a role in childhood B-cell precursor acute lymphoblastic leukemia PMID: 28947432
  4. this study shows that alteration in Ikaros expression promotes B-1 cell differentiation into phagocytes PMID: 29107383
  5. Our results demonstrate that the IKAROS promotes PHF2 expression, and suggest that PHF2 (low) expression works with the IKAROS gene deletion to drive oncogenesis of ALL PMID: 28994305
  6. present case provides the first definitive evidence on the ability of an IKAROS heterozygous mutation to cause both immunodeficiency and NOTCH1-driven T-ALL in humans PMID: 28096536
  7. Casein kinase II, glycogen synthase kinase-3, and Ikaros mediated regulation of leukemia has been summarized. (Review) PMID: 28623166
  8. Results found Ikaros directly binding the DNM2 promoter and suppresses DNM2 expression in ALL tumors and cell lines. PMID: 27885263
  9. there is a clear distinction between loss-of-function and dominant-negative IKZF1 deletions. Affected patients should thus be monitored for minimal residual disease carefully to detect incipient relapses at an early stage and they are potential candidates for alternative or intensified treatment regimes. PMID: 28751559
  10. IKZF1 gene deletion is associated with acute lymphoblastic leukemia. PMID: 27588474
  11. data reveal the mechanism by which chromatin remodeling and target gene expression are regulated by Ikaros alone and in complex with HDAC1 in B-ALL PMID: 26639180
  12. Ikaros regulates expression of the BCL6/BACH2 axis in acute lymphoblastic leukemia cells. PMID: 28030830
  13. high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of acute lymphoblastic leukemia PMID: 27391346
  14. expression of both CEBPE and IKZF1 in patient leukemic B cells was most similar to that in early stage B cells, believed to be the B-ALL cell-of-origin PMID: 26437776
  15. we identified IKZF1 as a novel regulator of glucocorticoid -induced transcriptional responses and a critical determinant of glucocorticoid -mediated cell death in normal and leukemic B cells PMID: 26713593
  16. We systematically screened 6 potentially functional SNPs in ARID5B and IKZF1 genes. PMID: 29292192
  17. Two families with a Common variable immunodeficiency-like syndrome with normal hematologic parameters and fetal hemoglobulin silencing with heterozygote IKZF1 mutations. PMID: 27581358
  18. IKZF1 rs10235796 C allele, IKZF1 rs6964969A>G, CDKN2A rs3731246 G>C, and CDKN2A rs3731246 C allele were signi fi cantly associated with Acute Lymphoblastic Leukemia in Yemenis of Arab-Asian descent. Borderline association found in IKZF1 rs4132601 T>G variant. No associations found with IKZF1 rs11978267 or rs7789635, DDC rs3779084; rs880028; rs7809758, CDKN2A rs3731217, CEBPE rs2239633; rs12434881 PMID: 28768142
  19. Silence of IKZF1 expression in MHCC-LM3 and MHCC-97L cell lines revealed a approximately 1.84- and approximately 2.27-fold rise in MDIG mRNA levels. PMID: 28471446
  20. Data show that six patients had large interstitial deletions starting within intronic regions of COBL at diagnosis, which is ~611 Kb downstream of IKZF1, suggesting that COBL is a hotspot for IKZF1 deletion (DeltaIKZF1). PMID: 27419633
  21. This study provides the first evidence for the association of IKZF1 variants with diffuse large B-cell lymphoma outcome PMID: 28879630
  22. showed that PTEN induced miR-26b expression by regulating the differential expression of Ikaros isoforms that are transcriptional regulators of miR-26b PMID: 28280276
  23. These results show that the mechanism of action of lenalidomide in ABC-DLBCL cells involves downregulation of SPIB transcription by cereblon-induced degradation of IKAROS. PMID: 28893618
  24. IKZF1 and IKZF3 expressions were associated with longer median progression free survival and overall survival in multiple myeloma patients PMID: 27881177
  25. Phosphorylation of Ikaros by CK2 impairs Ikaros DNA-binding ability, as well as Ikaros ability to regulate gene expression and function as a tumor suppressor in leukemia. (Review) PMID: 27666503
  26. High IKZF1 expression is associated with multiple myeloma. PMID: 28017969
  27. bioinformatics analysis indicated that both SNPs were located in a putative enhancer area in immune-related cell lines and tissues. A protein-protein interaction analysis found that IKZF1, together with GTF2I (an SS susceptibility gene newly identified through GWAS), could interact with histone deacetylase family proteins. In summary, this is the first study to report an association between IKZF1 and SS in Han Chinese PMID: 28552951
  28. The M4 motif (ACTAYRNNNCCCR) is a functional regulatory bipartite cis-element, which engages a THAP11/HCF-1 complex via binding to the ACTAYR module, while the CCCRRNRNRC subsequence part constitutes a binding platform for Ikaros and NFKB1 PMID: 27576892
  29. Germline heterozygous IKZF1 mutations cause dysgammaglobulinemia, hematologic abnormalities (including B-cell defects), and autoimmune diseases PMID: 27939403
  30. Results suggest that the rs1456896 A allele is associated with protective susceptibility to lupus nephritis. However, this association did not seem to be implicated in the disease and histopathological severity of lupus nephritis in the current population, a northern Han Chinese cohort. PMID: 27684961
  31. elevated Ctnnd1 expression contributes to maintenance of murine B-ALL cells with compromised Ikaros function. PMID: 28190000
  32. the presence of IKAROS deletion in acute lymphoblastic leukemia in Mexican Mestizos patients could represent a poor-prognosis marker and was probably related to therapy failure PMID: 27623040
  33. Sumoylated Ikaros is less effective than unsumoylated forms at inhibiting the expansion of murine leukemic cells, and Ikaros sumoylation is abundant in human B-cell acute lymphoblastic leukemic cells, but not in healthy peripheral blood leukocytes. Our results suggest that sumoylation may be important in modulating the tumor suppressor function of Ikaros PMID: 27315244
  34. our results identify BTG1 as a tumor suppressor in leukemia that, when deleted, strongly enhances the risk of relapse in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia, and augments the glucocorticoid resistance phenotype mediated by the loss of IKZF1 function. PMID: 27979924
  35. ETV6 and IKZF1 are transcriptional regulators not just of ERG, but also of a number of genes regulated by a densely interconnected network of seven transcription factors. PMID: 27604872
  36. results suggest that CRBN binds to Ikaros via its N-terminal region and regulates transcriptional activities of Ikaros and its downstream target, enkephalin PMID: 27329811
  37. revealed more than 170 NFAT-associated proteins, half of which are involved in transcriptional regulation. Among them are many hitherto unknown interaction partners of NFATc1 and NFATc2 in T cells, such as Raptor, CHEK1, CREB1, RUNX1, SATB1, Ikaros, and Helios. PMID: 27637333
  38. this study shows that Ikaros undergoes a transient increase in protein levels at the transitional single-positive CD8+ developmental stage before diverging in their expression patterns at later stages PMID: 27502439
  39. variants within IKZF1, ARID5B, and CEBPE were associated with pediatric ALL risks. PMID: 27184773
  40. FISH studies showed false-negative results in 10, 40, and 28% of the samples tested for the IKZF1,PAX5, and CDKN2A/B gene deletions, respectively. The PAX5 and IKZF1 abnormalities are highly specific to B-ALL and can be used as diagnostic markers PMID: 28214896
  41. The impact of IKZF1 polymorphisms on childhood ALL risk. PMID: 26790447
  42. Genotypic and allelic frequencies differed significantly between cases and controls at IKZF1-rs4132601 (p=0.039, p=0.015) and ARID5B-rs10821936 (p=0.028, p=0.026). PMID: 27644650
  43. These data suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons without BCR-ABL1 and those receiving chemotherapy-only. PMID: 27067989
  44. Data indicate an oncogenic role for an Ikaros protein/MYCBP2 protein/proto-oncogene protein c-MYC axis in adult acute lymphoblastic leukemia (ALL), providing a mechanism of target therapies that activate Ikaros in ALL. PMID: 26517351
  45. The anti-PEL effects of IMiDs involved cereblon-dependent suppression of IRF4 and rapid degradation of IKZF1, but not IKZF3. Small hairpin RNA-mediated knockdown of MYC enhanced the cytotoxicity of IMiDs PMID: 26119939
  46. A novel, non-canonical splice variant of the Ikaros gene (Ik11) is aberrantly expressed in B-cell lymphoproliferative disorders. PMID: 23874502
  47. the presented data suggest a mechanism through which Ikaros and HDAC1 regulate the epigenetic signature in leukemia: via regulation of JARID1B transcription. PMID: 26655717
  48. IKZF1 deletions were detected in 28.7% B-ALL patients, were more common in BCR-ABL positive and adult B-ALL, and correlated with higher induction failure PMID: 26704074
  49. all variants of rare IKZF1 deletions are associated with an unfavorable prognosis in pediatric BCP-ALL. PMID: 26202931
  50. We conducted a genome-wide association study for Cold Medicine related -Stevens-Johnson Syndrome /Toxic epidermal necrolysis with SOCs and found that IKZF1 single-nucleotide polymorphisms (SNPs) were significantly associated. PMID: 26448174

Show More

Hide All

Involvement in disease Immunodeficiency, common variable, 13 (CVID13)
Subcellular Location Nucleus, Note=In resting lymphocytes, distributed diffusely throughout the nucleus, Localizes to pericentromeric heterochromatin in proliferating cells, This localization requires DNA binding which is regulated by phosphorylation / dephosphorylation events, SUBCELLULAR LOCATION: Isoform Ik2: Nucleus
Protein Families Ikaros C2H2-type zinc-finger protein family
Tissue Specificity Abundantly expressed in thymus, spleen and peripheral blood Leukocytes and lymph nodes. Lower expression in bone marrow and small intestine.
Database Links

HGNC: 13176

OMIM: 603023

KEGG: hsa:10320

STRING: 9606.ENSP00000331614

UniGene: Hs.435949


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1